Timing of health technology assessment in the United States: An evaluation of ICER reviews over 8 years

Journal of Managed Care and Specialty Pharmacy · Published 2026-06-24 · DOI 10.18553/jmcp.2026.32.7.872

Free full text

Authors (4)

Abigail C. Wright, Avery McKenna, Belén Herce-Hagiwara, Foluso Agboola

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wright, A., McKenna, A., Herce-Hagiwara, B., et al. (2026). Timing of health technology assessment in the United States: An evaluation of ICER reviews over 8 years. Journal of Managed Care and Specialty Pharmacy. https://doi.org/10.18553/jmcp.2026.32.7.872

Related articles

• Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Principles and practices for successful gene therapy innovative contracting: Insights from a multistakeholder convening · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Patient experience data in formulary decision-making: Payer-reported perceptions and use · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Evaluating the design and implementation challenges of the Centers for Medicare & Medicaid Services’ Cell and Gene Therapy Access Model · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• US commercial health plan use of corticosteroids in step therapy protocols: Frequency and clinical appropriateness · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Advancing the measurement of caregiver impact: Data collection priorities aligned with caregiver, health technology assessment, and policy stakeholders · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Shared visits vs incident-to billing for pharmacy services · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal